Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 2/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7721210 | 0.98 | LGMN (0.45) | LGMNPRKDCMAPTALDH1A1PIK3CA | |
| SCHEMBL4094752 | 0.93 | LGMN (0.46) | LGMNPRKDCMAPTALDH1A1PIK3CA | |
| SCHEMBL22003311 | 0.90 | LGMN (0.50) | LGMNPRKDCMAPTALDH1A1PIK3CA | |
| SCHEMBL30505441 | 0.89 | LGMN (0.49) | LGMNPRKDCMAPTALDH1A1PIK3CA | |
| SCHEMBL23153727 | 0.87 | LGMN (0.44) | LGMNPRKDCMAPTALDH1A1PIK3CA | |
| SCHEMBL24179133 | 0.87 | MAPT (0.47) | LGMNPRKDCMAPTALDH1A1PIK3CA | |
| SCHEMBL21382460 | 0.86 | POLB (0.51) | LGMNPRKDCMAPTALDH1A1PIK3CA | |
| SCHEMBL19174694 | 0.86 | MAPT (0.54) | LGMNPRKDCMAPTALDH1A1PIK3CA | |
| SCHEMBL20764155 | 0.84 | MAPT (0.58) | MAPTALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL23759566 | 0.83 | ALDH1A1 (0.46) | LGMNPRKDCMAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0877298-B1 | Coated xerographic photographic paper | XEROX CORP (US) | 2001-08-29 | — | — | EP | claimed |
| US-8263590-B2 | Pyrimidine derivatives | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8263590-B2 | Pyrimidine derivatives | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| EP-1660458-B1 | 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| US-20110201606-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| US-20110201606-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| US-7964592-B2 | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2011-06-21 | — | — | US | disclosed |
| US-7964592-B2 | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2011-06-21 | — | — | US | disclosed |
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
| US-7893074-B2 | inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide | NOVARTIS AG (CH) | 2011-02-22 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| EP-0333005-A1 | Light-sensitive dialkoxybenzenediazonium compound, method for its preparation and its use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-09-20 | — | — | EP | disclosed |
| US-4642383-A | 2,21-DIHYDROXYDIPHENYL SULFIDES, SULFOXIDES, AND SULFONES | JAMES RIVER GRAPHICS, INC. (US) | 1987-02-10 | — | — | US | disclosed |
| EP-0014982-B1 | TWO-COMPONENT DIAZOTYPE MATERIAL | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-07-28 | — | — | EP | disclosed |
| US-4273850-A | 2,5-DIALKOXY-4-ARYLMERCAPTOBENZENE DIAZONIUM SALTS AND A HYDROXYNAPHTHALENE DISULFONAMIDE COUPLER | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-06-16 | — | — | US | disclosed |
| EP-0014982-A2 | Two-component diazotype material | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-09-03 | — | — | EP | disclosed |
| US-3976491-A | DIAZONIUM SALT, DIHYDROXYBENZENE COUPLER | SCOTT PAPER COMPANY (US) | 1976-08-24 | — | — | US | disclosed |
| US-3971663-A | CYANOACETAMIDO NAPHTHALENES | OCE-BRUNING, INC. A CORP. OF DELAWARE | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | TYMS, TYMP, DPYD | LGMN 4186/4885PRKDC 1252/4885MAPT 2197/4885 |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | LGMN 3964/4885PRKDC 1185/4885MAPT 2178/4885 |
| US-20110201606-A1 | PYRIMIDINE DERIVATIVES | DPYD, TYMP, TYMS | LGMN 4726/4885PRKDC 723/4885MAPT 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.